ИНФЕКЦИЯ С CYTOMEGALOVIRUS ПРИ ПАЦИЕНТИ С ВЪЗПАЛИТЕЛНИ ЧРЕВНИ ЗАБОЛЯВАНИЯ
Ключови думи :
Cytomegalovirus, CMV асоцииран колит, цитомегаловирусна инфекция, възпаление, възпа- лителни чревни заболявания, улцерозен колит, болест на Крон, опортюнистична инф екцияАбстракт
Въпреки многобройните проучвания ролята на инфекцията с Cytomegalovirus (CMV) върху тежест-
та и влошаването на възпалението, както и резистентността към лечение при пациенти с възпалителни чревни заболявания (ВЧЗ) продължава да е актуална тема. През последните години ролята на CMV при обострянията на ВЧЗ е силно обсъждана. Редица автори подкрепят активната роля на CMV при обострянията
на ВЧЗ, докато други насърчават концепцията за “невинния” страничен наблюдател, подкрепяйки тезата, че инфекцията с CMV не участва в прогресирането на заболяването. Настоящият литературен обзор има за цел задълбочено да разгледа актуализираната представа за аспекти, свързани с насложена инфекция с CMV при пациенти с ВЧЗ, включително епидемиология, рискови фактори, клинични характеристики, диагностични тестове, място на имуносупресорите, както и показанията за антивирусно лечение.
Литература (библиография)
Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med, 2020, 383(27):2652–2664.
Khan S et al. Factors influencing the quality of life in inflammatory bowel disease: A comprehensive review. Dis Mon, 2024, 70(1):101672.
Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S. Inflammatory bowel disease: estimates from the global burden of disease 2017 study. Aliment Pharmacol Ther, 2020, 51(2):261–270.
Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021, 160(5):1570–1583.
Mirchev M, Peruhova M, Boeva I, Stoitsov V. Inflammatory Bowel Disease – Current and Future Perspectives of the Biological Treatment. Bulg J Hepatogastroenterology, 2023, (1):1–8.
Toruner M et al. Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease. Gastroenterology, 2008, 134(4):929–936.
Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr, 2016, 4(4).
Zuhair M et al. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol, 2019, 29(3):1–6.
Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol, 2020, 223(3):330–349.
Rowshani AT, Bemelman FJ, van Leeuwen EMM et al. Clinical and Immunologic Aspects of Cytomegalovirus Infection in Solid Organ Transplant
Recipients. Transplantation, 2005, 79(4):381–386.
Serquiña AK, Ziegelbauer JM. How herpesviruses pass on their genomes. J Cell Biol, 2017, 216(9):2611–2613.
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol, 2021, 19(12):759–773.
Siegmund B. Cytomegalovirus infection associated with inflammatory bowel disease. Lancet Gastroenterol Hepatol, 2017, 2(5):369–376.
Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol, 2006.
Powell RD, Warner NE, Levine RS, Kirsner JB. Cytomegalic inclusion disease and ulcerative colitis. Am J Med, 1961, 30(2):334–340.
Römkens TEH. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol, 2016, 22(3):1321.
Lv Y et al. Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis. Infect Drug Resist, 2017, 10:511–519.
Garrido E. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol, 2013,19(1):17.
Lopes S et al. Looking into Enteric Virome in Patients with IBD. Inflamm Bowel Dis, 2017, 23(8):1278–1284.
Roblin X et al. Prevalence of Cytomegalovirus Infection in Steroid-refractory Crohn’s Disease. Inflamm Bowel Dis, 2012, 18(7):E1396–E1397.
Al-Zafiri R, Gologan A, Galiatsatos P, Szilagyi A. Cytomegalovirus complicating inflammatory bowel disease: A 10-year experience in a community-based, university-affiliated hospital. Gastroenterol Hepatol, 2012, 8(4):230–239.
Kishore J et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol, 2004, 53(11):1155–1160.
Yadegarynia D et al. Prevalence of cytomegalovirus infection in patients with ulcerative colitis: A prospective cross-sectional study in Tehran, Iran. Iran J Microbiol, 2018, 10(5):342–347.
Kim JJ, Simpson N, Klipfel N et al. Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease. Dig Dis Sci, 2010, 55(4):1059–1065.
Gauss A et al. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease. Eur J Gastroenterol Hepatol, 2015, 27(6):712–720.
McCurdy JD et al. A Model for Identifying Cytomegalovirus in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol, 2015, 13(1):131–137.
Qin Y et al. Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis. Diagnostics, 2021, 11(11):1952.
Jentzer A et al. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms, 2020, 8(7):1078.
Lee H-S et al. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis, 2016, 22(4):912–918.
Kim YS et al. The Prevalence and Efficacy of Ganciclovir on Steroid-refractory Ulcerative Colitis With Cytomegalovirus Infection. J Clin Gastroenterol, 2012, 46(1):51–56.
Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials. Am J Gastroenterol, 2013, 108(8):1268–1276.
Sandborn WJ et al. Safety of Tofacitinib for Treatment of Ulcerative
Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol, 2019, 17(8):1541–1550.
Rawa-Gołębiewska A, Lenarcik M, Zagórowicz E. Resolution of CMV Infection in the Bowel on Vedolizumab Therapy. J Crohn’s Colitis,
, 13(9):1234–1235.
Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohn’s Colitis, 2020, 14(8):1162–1171.
Nguyen M, Bradford K, Zhang X, Shih DQ. Cytomegalovirus Reactivation in Ulcerative Colitis Patients. Ulcers, 2011, 2011:1–7.
Levin A, Yaari S, Stoff R et al. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion, 2017, 96(3):142–148.
Wu X, Wu L, Ji H, Wang F. Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis. Dig Dis Sci, 2015, 60(11):3203–3208.
Zhang C, Krishna SG, Hinton A et al. Cytomegalovirus-Related Hospitalization Is Associated With Adverse Outcomes and Increased
Health-Care Resource Utilization in Inflammatory Bowel Disease. Clin Transl Gastroenterol, 2016, 7(3):e150.
Yoon J et al. Endoscopic features and clinical outcomes of cytomegalovirus gastroenterocolitis in immunocompetent patients. Sci Rep, 2021, 11(1):6284.
Kucharzik T et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohn’s Colitis, 2021, 15(6):879–913.
Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis, 2016, 22(12):2966–2976.
Lamb CA et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68(Suppl 3):s1–s106.
Sager K, Alam S, Bond A et al. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther, 2015, 41(8):725–733.
Jones A et al. Effects of Antiviral Therapy for Patients With Inflammatory
Bowel Disease and a Positive Intestinal Biopsy for Cytomegalovirus. Clin Gastroenterol Hepatol, 2015, 13(5):949–955.
Kopylov U. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis. World J Gastroenterol, 2014, 20(10):2695.
Shukla T, Singh S, Loftus EV et al. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus. Inflamm Bowel Dis, 2015, 21(11):2718–2725.
Pillet S. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol, 2016, 22(6):2030.
Meeralam Y et al. Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy. Cureus, 2023, 15(2):10–13.
Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: Pathogen or innocent bystander? Inflamm Bowel Dis, 2010, 16(9):1620–1627.
Criscuoli V et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis, 2004, 36(12):818–820.
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Авторски права (c) 2026 P. Peneva, H. Valkov, B. Vladimirov, P. Penchev (Author)
Публикация с Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Можете свободно да споделяте, копирате и разпространявате материала във всякакъв носител или формат при следните условия.
